<DOC>
	<DOCNO>NCT01071954</DOCNO>
	<brief_summary>This extension study design ass safety durability platelet count increase romiplostim treatment thrombocytopenic subject Immune ( Idiopathic ) Thrombocytopenia Purpura . This study available pediatric subject complete previous romiplostim ITP study meet eligibility criterion study .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Long-term Dosing Romiplostim Thrombocytopenic Pediatric Subjects With Immune ( Idiopathic ) Thrombocytopenia Purpura</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<criteria>Subject subject 's legally acceptable representative provide informed consent . Subject complete romiplostim study treatment thrombocytopenia pediatric subject ITP . Subject previously bone marrow stem cell disorder ( abnormal bone marrow finding typical ITP must approve Amgen subject may enrol study ) . Subject new active malignancy diagnose since enrollment previous romiplostim ITP study . Subject receive alkylating agent within four week screen visit anticipate use time propose study . Other investigational medication exclude . Currently enrol another investigational device drug study , less 30 day since end another investigational device drug study ( ) , receive investigational agent ( ) ( exception romiplostim previous clinical study ) . Female subject child bear potential ( define first menses ) willing use highly effective contraception treatment 4 week end treatment . Female subject pregnant breast feeding , plan become pregnant within 4 week end treatment . Subject know sensitivity product administer dosing . Subject previously enter study ( depend type study ) . Subject available protocol require study visit , best subject investigator 's knowledge . Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply require study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immune thrombocytopenic Purpura</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>